Your browser doesn't support javascript.
loading
Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.
Chevli, K Kent; Shore, Neal D; Trainer, Andrew; Smith, Angela B; Saltzstein, Daniel; Ehrlich, Yaron; Raman, Jay D; Friedman, Boris; D'Anna, Richard; Morris, David; Hu, Brian; Tyson, Mark; Sankin, Alexander; Kates, Max; Linehan, Jennifer; Scherr, Douglas; Kester, Steven; Verni, Michael; Chamie, Karim; Karsh, Lawrence; Cinman, Arnold; Meads, Andrew; Lahiri, Soumi; Malinowski, Madlen; Gabai, Nimrod; Raju, Sunil; Schoenberg, Mark; Seltzer, Elyse; Huang, William C.
Affiliation
  • Chevli KK; State University of New York at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York.
  • Shore ND; Atlantic Urology Clinics, Carolina Urologic Research Center, Myrtle Beach, South Carolina.
  • Trainer A; Adult Paediatrics Urology & Urogynecology, Omaha, Nebraska.
  • Smith AB; University of North Carolina School of Medicine, Chapel Hill, North Carolina.
  • Saltzstein D; Urology San Antonio, San Antonio, Texas.
  • Ehrlich Y; Rabin Medical Center, Petah-Tikva, Israel.
  • Raman JD; Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania.
  • Friedman B; Lady Davis Carmel Medical Center, Technicon-Israel Institute of Technology, Haifa, Israel.
  • D'Anna R; Arkansas Urology, Little Rock, Arkansas.
  • Morris D; Urology Associates, Nashville, Tennessee.
  • Hu B; Loma Linda University, Loma Linda, California.
  • Tyson M; Mayo Clinic, Scottsdale, Arizona.
  • Sankin A; Albert Einstein College of Medicine, Bronx, New York.
  • Kates M; Brady Urological Institute, Johns Hopkins Medicine, Baltimore, Maryland.
  • Linehan J; John Wayne Cancer Institute, Santa Monica, California.
  • Scherr D; Weill Medical College of Cornell University, New York, New York.
  • Kester S; Urology Center of Florida, Pompano Beach, Florida.
  • Verni M; Urology Center of Las Vegas, Las Vegas, Nevada.
  • Chamie K; UCLA, Los Angeles, California.
  • Karsh L; The Urology Center of Colorado, Denver, Colorado.
  • Cinman A; Tower Urology, Los Angeles, California.
  • Meads A; UroGen Pharma, New York, New York.
  • Lahiri S; UroGen Pharma, New York, New York.
  • Malinowski M; UroGen Pharma, New York, New York.
  • Gabai N; UroGen Pharma, New York, New York.
  • Raju S; UroGen Pharma, New York, New York.
  • Schoenberg M; Albert Einstein College of Medicine, Bronx, New York.
  • Seltzer E; UroGen Pharma, New York, New York.
  • Huang WC; UroGen Pharma, New York, New York.
J Urol ; 207(1): 61-69, 2022 01.
Article in En | MEDLINE | ID: mdl-34433303
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Mitomycin / Hydrogels / Antibiotics, Antineoplastic Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: J Urol Year: 2022 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Mitomycin / Hydrogels / Antibiotics, Antineoplastic Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: J Urol Year: 2022 Type: Article